Extracorporeal photopheresis (ECP) is the first FDA approved cellular photoimmunotherapy for cancer and has demonstrated efficacy in T-cell mediated disorders including prevention and treatment of acute and chronic graft-versus-host disease, organ transplant rejection, scleroderma, Crohn’s disease and diabetes mellitus.